Skip Navigation

QJM 2007 100(9):591-593; doi:10.1093/qjmed/hcm068
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kurisu, S.
Right arrow Articles by Aokage, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurisu, S.
Right arrow Articles by Aokage, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Role of medications in symptomatic hyperkalemia

The first 10% of the full text of this article appears below.

Sir,

In recent years, angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs), spironolactone and beta-adrenergic antagonists have been used to treat heart failure as first-line therapy.1 However, these medications can cause hyperkalaemia as a side-effect.2 We evaluated the medications and clinical profiles of patients with symptomatic hyperkalaemia in recent years.

We studied . . . [Full Text of this Article]

S. Kurisu, I. Inoue, T. Kawagoe, M. Ishihara, Y. Shimatani, Y. Nakama, T. Maruhashi, E. Kagawa, K. Dai and T. Aokage

Department of Cardiology
Hiroshima City Hospital
Naka-ku
Hiroshima
Japan

email: skurisu@nifty.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?